2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
17
Prostatic Neoplasms
6
Ovarian Neoplasms
6
Neoplasms
5
Triple Negative Breast Neoplasms
4
Neoplasm Metastasis
4
Stomach Neoplasms
3
Endometrial Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Solid Tumors
2
Multiple Myeloma
2
Mouth Neoplasms
2
Lymphoma
2
Laryngeal Neoplasms
2
Hypopharyngeal Neoplasms
2
Glioblastoma
2
Fallopian Tube Neoplasms
2
Carcinoma
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Cancers
1
Skin Diseases
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms, Castration-Resistant
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Interventions
tucatinib
1
pralsetinib
1
pertuzumab
1
ipatasertib
1
inavolisib
1
entrectinib
1
atezolizumab
1
alectinib
1
Trastuzumab
1
Tiragolumab
1
Paclitaxel
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Advanced Unresectable or Metastatic Solid Malignancy
×
ipatasertib
×
Clear all
NCT04632992
2025-01-08
MyTACTIC
Genentech, Inc.
Phase 2
Completed
252 enrolled
27 charts